1058730-22-5

Basic information

• Product Name: 7-(furan-3-ylcarbonyl)-2,7-diazabicyclo[3.3.0]octane
• Synonyms: 7-(furan-3-ylcarbonyl)-2,7-diazabicyclo[3.3.0]octane
• CAS NO: 1058730-22-5
• Molecular Weight: 206.244
• Mol File: 1058730-22-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 7-(furan-3-ylcarbonyl)-2,7-diazabicyclo[3.3.0]octane(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(furan-3-ylcarbonyl)-2,7-diazabicyclo[3.3.0]octane(1058730-22-5)
• EPA Substance Registry System: 7-(furan-3-ylcarbonyl)-2,7-diazabicyclo[3.3.0]octane(1058730-22-5)

Safety Data

• Hazardous Substances Data: 1058730-22-5(Hazardous Substances Data)

Upstream product

• 488-93-7 3-Furoic acid 
• 185693-02-1 hexahydropyrrolo[3,4-b]pyrrole-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS

A compound of Formula 1: A-C(O)-Cy, wherein A is a diazabicyclic core, containing 7, 8, or 9 ring atoms, and selected from the following: 2,6-diazabicyclo[3.2.0]heptane; 3,6-diazabicyclo[3.ZO]heptane; 2,7-diazabicyclo[4.2.0]octane; 3,7-diazabicyclo[4.2.0]octane; 3,8-diazabicyclo[4.2.0]octane; 2,7-diazabicyclo[3.3.0]octane; 2,7-diazbicyclo[4.3.0]nonane; 2,8-diazbicyclo[4.3.0]nonane; 3,7-diazabicyclo[4.3.0]nonane; 3,8-diazabicyclo[4.3.0]nonane; 3,9-diazabicyclo[4.3.0]nonane; 2,6-diazabicyclo[3.2.1 ]octane; 3,6-diazabicyclo[3.2.1]octane; wherein the diazabicycle is attached as a radical to the depicted carbonyl via either one of the two ring nitrogen atoms, such that the carbonyl forms an amide bond with the ring nitrogen; Cy is a heteroaryi group; The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α402 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds are believed to: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects, namely side effects such as significant Increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle.